Skip to main content

Advertisement

SpringerLink
Log in

Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma

  • Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

We measured urokinase-type plasminogen activator (u-PA) plasma levels in patients with various chronic liver diseases, including hepatocellular carcinoma (HCC), also measuring these levels in healthy volunteers. Plasma u-PA levels in the group of patients with decompensated liver cirrhosis (mean modified Pugh score of 14 points) were markedly elevated and significantly higher than those in the patients with decompensated liver cirrhosis with HCC (modified Pugh score of 10 points), those with compensated liver cirrhosis with HCC, and those with compensated liver cirrhosis. Patients in all these three latter groups had moderately and significantly elevated u-PA levels compared to levels in the chronic hepatitis group and the healthy volunteers, but the levels were not significantly different from each other. There was no relationship between u-PA plasma level and the type of HCC tumor invasion or number or size of tumors. Significant correlations were found between u-PA plasma levels and the results of seven different liver function tests in three groups without associated HCC; u-PA antigen and prothrombin time (%), hepaplastin test (%), serum cholinesterase, serum albumin, serum total cholesterol, and indocyanine green clearance correlated negatively, while u-PA antigen and serum total bilirubin correlated positively. These results suggest that plasma u-PA is associated with deterioration of liver function but not with HCC invasion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Astrup T. Fibrinolysis: An overview. Progr Chem Fibrinol Thrombol 1978;3:1–57.

    CAS  Google Scholar 

  2. Hébert CA, Baker JB. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalization of cell surface urokinase with vinculin. J Cell Biol 1988;106:1241–1247.

    PubMed  Google Scholar 

  3. Pöllänen J, Saksela O, Salonen EM, et al. Distinet localization of urokinase-type plasminogen activator and its Type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987;104:1085–1096.

    PubMed  Google Scholar 

  4. Pöllänen J, Hedman K, Nielsen, LS et al. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988;106:87–95.

    PubMed  Google Scholar 

  5. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988;53:505–518.

    Article  CAS  PubMed  Google Scholar 

  6. Knudsen BS, Nachman RL. Matrix plasminogen activator inhibitor. J Biol Chem 1988;263:9476–9481.

    CAS  PubMed  Google Scholar 

  7. Wojta J, Hoover RL, Daniel TO. Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J Biol Chem 1989;264: 2846–2852.

    CAS  PubMed  Google Scholar 

  8. Cheng SM, Lee SG, Kalyan NK, et al. Isolation of a human cDNA of urokinase and its expression in COS-1 cells. Gene 1988;69:357–363.

    Article  CAS  PubMed  Google Scholar 

  9. Kjaeldgaard A, Larsson B, Åstedt B. Release of both urokinase and tissue plasminogen activator from veins in vitro. Thromb Res 1986;44:729–737.

    Article  CAS  PubMed  Google Scholar 

  10. Kasai S, Arimura H, Nishida M, et al. Primary structure of single-chain pro-urokinase. J Biol Chem 1985;260:12382–12389.

    CAS  PubMed  Google Scholar 

  11. Mangel WF, Lin B, Ramakrishnan V. Conformation of one- and two-chain high molecular weight urokinase analyzed by small-angle neutron scattering and vacuum ultraviolet circular dichroism. J Biol Chem 1991;266:9408–9412.

    CAS  PubMed  Google Scholar 

  12. Blasi F, Vassalli JD, Danø K. Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J Cell Biol 1987;104: 801–804.

    Article  CAS  PubMed  Google Scholar 

  13. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990;9:353–367.

    CAS  PubMed  Google Scholar 

  14. Corasanti JG, Celik C, Camiolo SM, et al. Plasminogen activator content of human colon tumors and normal mucosae: Separation of enzymes and partial purification. J Natl Cancer Inst 1980;65: 345–351.

    CAS  PubMed  Google Scholar 

  15. Markus G, Takita H, Camiolo SM, et al. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980;40:841–848.

    CAS  PubMed  Google Scholar 

  16. Camiolo SM, Markus G, Evers JL, et al. Plasminogen activator content of neoplastic and benign human prostate tissues: Fibrin augmentation of an activator activity. Int J Cancer 1981;27: 191–198.

    CAS  PubMed  Google Scholar 

  17. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator antigen is a predictor of early replase in breast cancer. Fibrinolysis 1990;4:69–78.

    Google Scholar 

  18. Kirchheimer JC, Huber K, Polterauer P, et al. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb Haemostasis 1985;54:617–618.

    CAS  Google Scholar 

  19. Levin EG, Fair DS, Loskutoff DJ. Human hepatoma cell line plasminogen activator. J Lab Clin Med 1983;102:500–508.

    CAS  PubMed  Google Scholar 

  20. Tsuji T, Higashi T, Yamada G, et al. Indication of orthotopic liver transplantation for adult liver diseases (in Japanese). Okayama Igakkai Zasshi 1991;103:155–165.

    Google Scholar 

  21. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649.

    CAS  PubMed  Google Scholar 

  22. Fletcher AP, Biederman O, Moore D, et al. Abnormal Plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: Its cause and consequences. J Clin Invest 1964;43:681–695.

    CAS  PubMed  Google Scholar 

  23. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984;37:772–777.

    CAS  PubMed  Google Scholar 

  24. Tran-Thang C, Fasel-Felley J, Pralong G, et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989;62:651–653.

    CAS  PubMed  Google Scholar 

  25. Huber K, Kirchheimer JC, Korninger C, et al. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. Thromb Res 1991;62:491–500.

    Article  CAS  PubMed  Google Scholar 

  26. Nogami T, Matsuno K, Kajii M, et al. Studies on metabolic fate of PPA in rats: (1) Absorption, distribution, metabolism, and excretion after single intravenous administration of125I-PPA (in Japanese). Kiso To Rinsho (Clin Report) 1987;21:6563–6578.

    Google Scholar 

  27. Nogami T, Matsuno K, Kasai S, et al. Studies on metabolic fate of PPA in rats: (2) Absorption, distribution, metabolism, and excretion after five successive intravenous administrations of125I-PPA (in Japanese) Kiso To Rinsho (Clin Report) 1987;21: 6579–6586.

    Google Scholar 

  28. Nogami T, Tsukada M, Tanaka K, et al. Studies on metabolic fate of UK in rats: Absorption, distribution, metabolism, and excretion after single intravenous administration of125I-UK (in Japanese). Igaku To Yakugaku (J Med Pharmaceut Sci) 1986;15: 877–898.

    Google Scholar 

  29. Collen D, De Cock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase-11. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984;52:24–26.

    CAS  PubMed  Google Scholar 

  30. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibition. Blood 1987;69:1315–1319.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, 700, Okayama, Japan

    Seiji Sato, Toshihiro Higashi, Souhei Ouguchi, Naoki Hino & Takao Tsuji

Authors
  1. Seiji Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiro Higashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Souhei Ouguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoki Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takao Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, S., Higashi, T., Ouguchi, S. et al. Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. J Gastroenterol 29, 745–750 (1994). https://doi.org/10.1007/BF02349281

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02349281

Key words

Search

Navigation